Now 2016 has come, but for Theranos, which was just revealed a serious fraud technically in 2015, the new year doesn’t seem good.

According to the latest report of The Wall Street Journal, when CMS inspected the Newark laboratory of Theranos located in northern California, it found it has existed some serious problems.

However, CMS has not released what kind of problems the laboratory exactly has to the public. But some CMS inspector revealed that the problems Theranos has this year are more severe than in 2013. During the inspection process of Theranos in 2013, inspectors had never seen the so-called "Edison device" patented technology which Theranos uses to analyze blood samples.

Interestingly, according to foreign media Business Insider reports, after CMS inspectors had checked the laboratory in northern California, Theranos got recognized from investors and got a new round financing of $ 630 million, but its valuation maintains no change at $ 9 billion, indicating that the new round investors of Theranos maintain a certain vigilance. About the revelation of the new problems, you can’t imagine what the investors will react. 

Some insider reveals that if Theranos can’t solve the existing problems timely, its severity may lead to disqualification of the laboratory involved in the federal Medicare program, and may even affect its cooperation with its largest partner Walgreens ( the famous American chain pharmacy) .

Brook, Vice president of Theranos , said the company has not yet received inspection report from CMS. However, according to The Wall Street Journal, it is expected that the results will soon be released to the public.